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Background: Common genetic variants in and around the gene 
encoding transcription factor 4 (TCF4) are associated with 
an increased risk of schizophrenia. Conversely, rare damag-
ing TCF4 mutations cause Pitt–Hopkins syndrome and have 
also been found in individuals with intellectual disability (ID) 
and autism spectrum disorder (ASD). Methods: Chromatin 
immunoprecipitation and next generation sequencing were 
used to identify the genomic targets of TCF4. These data 
were integrated with expression, epigenetic and disease 
gene sets using a range of computational tools. Results: We 
identify 10 604 TCF4 binding sites in the genome that were 
assigned to 5437 genes. De novo motif enrichment found 
that most TCF4 binding sites contained at least one E-box 
(5′-CAtcTG). Approximately 77% of TCF4 binding sites 
overlapped with the H3K27ac histone modification for active 
enhancers. Enrichment analysis on the set of TCF4 targets 
identified numerous, highly significant functional clusters for 
pathways including nervous system development, ion trans-
port and signal transduction, and co-expression modules for 
genes associated with synaptic function and brain develop-
ment. Importantly, we found that genes harboring de novo 
mutations in schizophrenia (P = 5.3 × 10−7), ASD (P = 2.5 
× 10−4), and ID (P = 7.6 × 10−3) were also enriched among 
TCF4 targets. TCF4 binding sites were also found at other 
schizophrenia risk loci including the nicotinic acetylcho-
line receptor cluster, CHRNA5/CHRNA3/CHRNB4 and 
SETD1A. Conclusions: These data demonstrate that TCF4 
binding sites are found in a large number of neuronal genes 
that include many genetic risk factors for common neurode-
velopmental disorders.
Key words:  transcription factor/gene expression/schizo
phrenia/psychiatric genetics/neurodevelopment/functio
nal genomics
Introduction
Genetic variants in and around the transcription factor 4 
(TCF4) gene are associated with range of disorders that 
are frequently associated with cognitive dysfunction.1–3 
The most recent schizophrenia GWAS reported three inde-
pendent single nucleotide polymorphisms (SNPs) in TCF4 
that surpassed the threshold for genome wide significance.4 
Intriguingly, rare TCF4 single nucleotide variants (SNVs) 
have also been described in schizophrenia patients, although 
their impact on the function of the protein has not been 
established.5,6 In addition to the genetic studies in schizo-
phrenia, TCF4 variants are associated with early informa-
tion processing and cognitive markers, some of which are 
schizophrenia endophenotypes.7–10 Damaging TCF4 muta-
tions have also been described in large-scale genotyping 
studies in patients with ID, neurodevelopmental disorders, 
and most recently ASD.11–15 Haploinsufficiency of TCF4 
causes Pitt–Hopkins syndrome (PTHS); a rare form intel-
lectual disability (ID) associated with characteristic facial 
features, autonomic dysfunction, and behavioral traits that 
resemble autism spectrum disorder (ASD).16–19 Collectively, 
these studies implicate TCF4 in a range of neurodevelop-
mental disorders.
TCF4 is a member of the basic helix-loop-helix 
(bHLH) family of proteins.20–22 For the purposes of 
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disambiguation, it should be noted that TCF4 (Gene ID: 
6925) described herein should not be confused with T-cell 
factor 4 (Gene ID: 6934, official gene symbol, TCF7L2) 
since they can share the same acronym. TCF4 and its par-
alogues, collectively known as E-proteins, interact with 
other bHLH proteins to regulate DNA binding specific-
ity and transcriptional activity at promoters and enhanc-
ers that contain E-boxes (5′-CANNTG).2,20,23 The human 
TCF4 gene encodes multiple protein isoforms of which 
only the major isoforms TCF4-A and TCF4-B have been 
characterized in detail.24 In neurons, TCF4 regulates the 
intrinsic excitability of pyramidal cells of the prefrontal 
cortex and has been shown to attenuate neurite branch-
ing.25,26 Furthermore, haploinsufficiency of Tcf4 in mice 
affects gene expression and DNA methylation in the 
brain, leading to enhanced long-term potentiation, learn-
ing and memory deficits, and autistic-like behavior.22,25,26 
By contrast, mice over-expressing Tcf4 in the brain dis-
play deficits in sensorimotor gating, fear conditioning, 
and circadian processes as well as impairments in atten-
tional and behavioral anticipation.7,27
Although the function of TCF4 as transcription factor 
has been well established, very little is known about the 
genes regulated by TCF4 in neuronal cells and specifically 
in cells of human origin. Therefore, to gain a functional 
insight into the role of TCF4 in schizophrenia other neu-
rodevelopmental disorders, we used a bespoke TCF4 
antibody for chromatin immunoprecipitation and next 
generation sequencing (ChIP-seq) to define the genomic 
targets of TCF4. We found that TCF4 target genes clus-
ter in neurodevelopmental pathways and are enriched for 
schizophrenia, ASD, and ID risk genes.
Materials and Methods
Detailed methods are provided in the supplementary 
material.
TCF4 Antibodies and Constructs
Rabbit polyclonal antibodies were raised against amino 
acids 361–554 (spanning TCF4-A and -B) of human 
TCF4-B fused to thioredoxin (TCF4_01) or glutathione 
S-transferase (TCF4_02), as described previously.28 Affinity 
purified antisera were tested extensively for specificity and 
reactivity by western blotting, immunoprecipitation, and 
mass spectrometry following ENCODE’s guidelines (sup-
plementary figure S1).29,30 TCF4 expression constructs 
were used as described previously while the myc-E47 con-
struct was kindly provided by Dr Carme Gallego.31
Chromatin Immunoprecipitation and Next Generation 
Sequencing
ChIP-seq was performed on TCF4-enriched chromatin 
prepared from human SH-SY5Y neuroblastoma cells fol-
lowing ENCODE’s guidelines.29,30 Enriched chromatin was 
processed and sequenced by Source BioScience using the 
Illumina TruSeq ChIP Sample Preparation Kit. Reads 
were aligned to the human reference genome (UCSC/h19) 
with BWA (version 0.7.5a) using the MEM algorithm with 
default parameters.32 Peaks were called according to the 
ENCODE irreproducible discovery rate (IDR) analysis 
pipeline (https://sites.google.com/site/anshulkundaje/proj-
ects/idr). These data are available from the Gene Expression 
Omnibus (GEO) database with the accession number 
GSE96915 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE96915). The HOMER ChIP-seq analysis 
package33 was used to annotate peaks, link them to nearest 
transcription start site and for motif analysis. All identified 
peaks were considered for annotation and analysis.
Gene Set Enrichment Analysis
Gene set/pathway enrichment analysis was performed 
using DAVID.34,35 All genes annotated with a TCF4 peak 
were considered and the whole genome used as back-
ground. For analyses using gene expression data, only 
those genes present on the microarray were used as back-
ground. Enrichment analysis using custom genes sets was 
performed using the Fisher’s exact test implemented in 
STATA 12.0 or R using the appropriate background lists 
(eg, genes detected on a microarray, protein coding genes, 
etc.) cited in each publication. Lists of genes contain-
ing de novo variants identified in patients and controls 
were obtained from Fromer et al.36 FMRP targets were 
obtained from Darnell et al,37 whereas the list of loss of 
function (LoF) intolerant human genes was obtained 
from Lek et al.38 Further details of these custom gene sets 
are provided in the supplementary material. Enrichment 
of TCF4 target genes at schizophrenia risk loci was inves-
tigated using the multi-marker analysis of genomic an-
notation (MAGMA) package using a 10 kb window as 
described previously.39,40
Results
Identification of Genomic TCF4 Binding Sites by 
ChIP-seq
To perform chromatin immunoprecipitation (ChIP) 
experiments we generated TCF4 polyclonal antibodies 
(TCF4_01 and TCF4_02) that would detect the 2 major 
TCF4 isoforms, TCF4-A and TCF4-B. Antibodies were 
tested for their specificity and ability to immunoprecipi-
tate TCF4 in SH-SY5Y cells following the ENCODE 
guidelines.29 SH-SY5Y neuroblastoma cells are one of 
the most widely used cell models to study neurodevel-
opmental processes and have been extensively used for 
neuropsychiatric research. TCF4_01 specifically detected 
over-expressed and endogenous TCF4 in SH-SY5Y cells 
but did not detect the TCF4 paralogue E47 (TCF3) 
(supplementary figure S1A). Mass spectrometry con-
firmed that TCF4_01 and TCF4_02 immunoprecipitated 
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endogenous TCF4-A and TCF4-B isoforms from 
SH-SY5Y cells (supplementary figures S1B and S1C).
High throughput sequencing of TCF4 and IgG ChIP 
samples produced greater than 2.2 × 107 reads per sample 
with Phred quality scores (>Q30) of 98.34% or higher. 
MACS 2.0 detected 10 604 high confidence peaks, span-
ning 0.18% of the genome, from duplicate samples that 
passed IDR analysis. These peaks are distributed around 
transcriptional start sites (TSSs) but are located primarily 
in intronic or intergenic regions of the genome (figures 
1A and 1B). Only 4.3% of peaks occur in promoter re-
gions immediately 5′ of  the TSS (figure 1B).
DNA sequence motif  analysis of TCF4 bound regions 
of the genome using HOMER identified strong enrich-
ment of the Atoh1 (proneural atonal gene) E-box motif  
(P = 1 × 10−1003) compared to the whole genome. De novo 
motif  construction also confirmed the enrichment of an 
E-box motif  in these peaks, albeit with a slightly differ-
ent base composition (figure 1B). Implementing both the 
canonical and de novo E-box motif, we annotated each 
ChIP-seq peak with the number of E-boxes occurring 
within a 200  bp window of the peak maximum. 85.8% 
of all peaks contained at least one canonical E-box, with 
the most frequent count being 4, ie, 2 separate sites with 
a count given to each strand. A similar pattern was also 
observed for the nonpalindromic de novo motif.
TCF4 Binding Sites and Differentially Expressed Genes 
in TCF4-Depleted Cells
Each of the 10 604 peaks was mapped to the nearest TSS, 
resulting in 5436 unique target genes. Of these unique 
genes, 4218 were annotated as protein coding. To ex-
amine the relationship between TCF4 binding sites and 
gene expression, we compared the list of TCF4 target 
genes with those that were differentially expressed in 
TCF4-depleted SH-SY5Y cells.41 Of the 4819 differen-
tially expressed genes, only 922 (17.6%) contained TCF4 
binding sites (figure 1D). To search for functional TCF4 
binding sites as defined by Cusanovich et  al,42 we re-
stricted our analysis to TCF4 bound regions of the ge-
nome within 10 kb of a TSS. Of the 1310 genes that had 
TCF4 binding sites within 10kb of the TSS, 234 (17.9%) 
were differentially expressed in TCF4-depleted cells. 
Similarly, genes with a TCF4 binding site within 10 kb of 
the TSS were also under-represented among the differen-
tially expressed genes.
TCF4 bound genes were visualized using the 
Integrative Genomic Viewer (IGV) (figure 1E and sup-
plementary figure S2).43 Figure 1E shows a represen-
tative example of a TCF4 bound region at an intronic 
site within PAPPA2 (chr1:176570227-176570965). TCF4 
binding sites are centered around densely tiled sequence 
reads spanning approximately 750 bp of chromosome 1 
in the TCF4 ChIP track (anti-TCF4 pAb) encompassing 
5 canonical E-boxes (figure 1E). Importantly, these peaks 
are absent from the IgG track where affinity purified pre-
immune IgG was used as the immunoprecipitating an-
tibody. PAPPA2 is also down-regulated (−1.95-fold) in 
TCF4-depleted cells (figure 1E).41 Quantitative PCR con-
firmed that TCF4_01 enriched the TCF4 bound region 
of PAPPA2 (35.8-fold) compared to pre-immune IgG.
TCF4 Binding Sites Are Associated With Active 
Enhancers
To further annotate TCF4 binding sites to regulatory re-
gions of the genome, we used BEDtools to compare the 
distribution of TCF4 bound regions of the genome with 
the histone modifications, histone H3 lysine 27 acetyla-
tion (H3K27ac, active enhancers), histone H3 lysine 4 
monomethylation (H3K4me1, enhancers), and histone 
H3 lysine 4 trimethylation (H3K4me3, promoters) in 
SH-SY5Y cells. Intersecting the locations of the TCF4 
bound regions of the genome with those marked by 
H3K27ac revealed that 76.9% of the TCF4 bound regions 
of the genome overlap the H3K27ac histone mark (P < 
2.2 × 10−16, OR = 200.7, figure 2A). Comparison of the 
ontologies of TCF4 bound genes with those marked by 
H3K27ac showed that neurodevelopment processes were 
the top gene ontology (GO) terms for TCF4 (see below) 
whereas the top ontologies for H3K27ac were gene ex-
pression and cell cycle (figure 2B). Similarly, we examined 
the association of TCF4 bound regions of the genome 
with those marked by H3K4me1 and H3K4me3. In com-
mon with H3K27ac, 77.0% of TCF4 peaks were marked 
by H3K4me1 (P < 2.2 × 10−16, OR = 201.8). By contrast, 
only 1.67% of TCF4 peaks were marked by H3K4me3 
(P < 2.2 × 10−16, OR = 3.86) in accordance with the low 
percentage of TCF4 binding sites at the promoter-TSS 
region of genes (figure 1B).
TCF4 Regulates Gene Expression at the CHRNA5/
CHRNA3/CHRNB4 Locus
We further examined the relationship between TCF4 
bound regions of the genome and histone modifica-
tions at specific loci; focusing on TCF4 binding sites 
that mapped to common variant schizophrenia risk loci 
discovered by the Psychiatric Genomics Consortium 
(PGC2).4 We observed 4 TCF4 binding sites that mapped 
to the CHRNA5/CHRNA3/CHRNB4 locus that encodes 
subunits of the nicotinic acetylcholine receptor (nAChR) 
on chromosome 15 (figure  2C). Two TCF4 binding 
sites (chr15:78963775–78964722 and chr15: 78973914–
78974467) are located in an enhancer region marked by 
extensive H3K27ac. The 2 TCF4 peaks in this region 
interdigitate with the troughs of H3K27ac demarcat-
ing nucleosome-depleted regions of the genome that 
associated with dense transcription factor occupancy 
(figure  2D).44 At higher resolution, maximal sequence 
coverage spans 2 E-boxes located within the H3K27ac 
trough (figure 2E). Importantly, CHRNA3 and CHRNB4 
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Fig. 1. Chromatin immunoprecipitation and next generation sequencing (ChIP-seq) analysis of genomic transcription factor 4 (TCF4) 
binding sites. Genomic distribution of TCF4 ChIP-seq peaks centered around the transcriptional start site (A). Location of TCF4 
binding sites relative to genomic features (B). TCF4 consensus binding sites predicted from the motif  discovery program in HOMER (C). 
TCF4 binding sites are enriched at canonical E-boxes (Atoh1), while de novo motif  discovery identified a nonpalindromic E-box. Venn 
diagram showing the overlap between TCF4 targets and differentially expressed genes in TCF4-depleted cells (D). Statistical tests were 
performed against a background set of 16 318 expressed genes with TORAY 3D-Gene and HOMER annotations. TCF4 bound regions 
at PAPPA2 displayed using IGV (E). IGV plots for PAPPA2 (intron) showing tiled, unique sequence reads after PCR de-duplication. For 
comparative purposes, the control pre-immune IgG is also shown. The locations of canonical E-boxes within the locus are also shown.
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Fig. 2. Transcription factor 4 (TCF4) binding sites are enriched at active enhancers. Venn diagram showing the intersection of TCF4 
bound regions of genome with those marked with the H3K27ac in SH-SY5Ycells (A). Top ranked GO terms for TCF4 bound genes 
and genes marked by H3K27ac in SH-SY5Y cells (B). UCSC genome browser screenshot of the CHRNA5/A3/B4 locus on human 
chromosome 15 showing ChIP-seq peaks for H3K27ac and TCF4 (C). The 2 major TCF4 peaks (box) are found at an active enhancer 
(marked by extensive H3K27ac) upstream of CHRNB4. Enlarged view of panel C showing that TCF4 bound regions are located within 
histone-depleted regions (troughs) of the enhancer (D). Enlarged view of panel C showing the TCF4 peak maps to a pair of E-boxes 
(highlighted) with the sequence 5′-CAGCTG (E).
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are down-regulated (−1.30 and −1.35-fold, respectively) 
following knockdown of TCF4 in SH-SY5Y cells.41 These 
data suggest that TCF4 may regulate gene expression at 
the CHRNA5/CHRNA3/CHRNB4 locus demonstrating 
a functional association between two distinct schizo-
phrenia risk genes/loci.
Biological Processes Associated With TCF4 
Bound Genes
GO analysis on the 5436 unique target genes revealed 
highly significant enrichments of many gene categories. 
Five hundred thirty-six terms were significant at a q value 
<0.05 of which 312 were unique terms. The most signif-
icant term was “GO:0007399~nervous system develop-
ment” (figure 2B). Given the large number of significant 
terms we used EnrichmentMap to group and visualize 
these 312 terms.45 Nine clusters containing 6 or more 
terms were considered for further analysis (figure 2 and 
supplementary figure S3). Each cluster relates to distinct 
biology and we manually assigned descriptions based on 
the terms within each cluster. The 3 largest clusters relate 
to cation channel function, neurogenesis, development 
and morphology, and signaling (figure  2 and supple-
mentary figure S3). The remaining clusters include terms 
relating to apoptosis and mesenchymal cell differentia-
tion (supplementary figure S3) as identified previously.41
TCF4 Binding Sites Are Enriched in 
Neurodevelopmental Genes
To determine the physiological relevance of TCF4 bound 
genes in SH-SY5Y cells to gene expression in the human 
brain, we examined the enrichment of the complete list 
of TCF4 targets in a number of commonly used gene 
sets.37,38,46 Following the rationale that genome-wide co-
expression networks reflect biological processes essential 
to human neocortical development we mapped TCF4 tar-
gets onto co-expression modules described by Parikshak 
et al.46 TCF4 bound genes were enriched for modules 17 
and 18 but were significantly under-represented in mod-
ules 4, 6, 12, and 14 (table 1). Module 17 contains genes 
involved in synaptic transmission and cation channel 
activity and is also enriched for ASD genes (table  1).46 
Similarly, we also undertook gene set analysis on the 
list of targets recognized by the FMRP RNA-binding 
protein and LoF intolerant genes. The targets of the 
FMRP-RNA binding protein and LoF intolerant genes 
are enriched for genes that harbor both de novo and com-
mon and risk alleles for schizophrenia and other neurode-
velopmental disorders such as ASD and ID.4,36,47,48 TCF4 
bound genes were also highly enriched for FMRP targets 
and LoF intolerant genes (OR = 1.87 and 1.42, respec-
tively, P < 2.2 × 10−16) (table 1). Taken together these data 
suggest that TCF4 binds to genes in SH-SY5Y cells that 
Table 1. Gene Set Enrichment for TCF4 Targets in Cortical Expression Modules, FMRP Targets, and LoF Intolerant Genes
Module Ontologya P value P Corr. OR 95% CI
17 Synaptic transmission 8.34 × 10−8 1.50 × 10−6 1.55 1.32–1.81
18 Defense response 2.15 × 10−7 3.87 × 10−6 1.54 1.32–1.81
13 Synaptic transmission 3.77 × 10−3 NS 1.29 1.09–1.53
8 Negative regulation of neuron differentiation 1.26 × 10−1 NS 1.29 0.94–1.76
1 None 7.82 × 10−3 NS 1.29 1.07–1.54
11 Cell cycle 3.43 × 10−1 NS 1.11 0.89–1.37
15 Response to virus 4.94 × 10−1 NS 1.10 0.84–1.43
5 None 3.35 × 10−1 NS 1.09 0.91–1.30
16 Cation-transporting ATPase activity 6.48 × 10−1 NS 1.06 0.85–1.32
2 Zinc ion binding 9.28 × 10−1 NS 0.99 0.82–1.18
None None 2.66 × 10−1 NS 0.96 0.89–1.03
3 Nucleic acid metabolic processes 1.42 × 10−1 NS 0.88 0.74–1.04
9 Regulation of cellular amino acid metabolic 
process
4.46 × 10−2 NS 0.69 0.48–0.99
10 None 3.40 × 10−1 NS 0.62 0.26–1.49
6 None 8.76 × 10−5 1.58 × 10−3 0.54 0.39–0.75
12 None 7.28 × 10−6 1.31 × 10−4 0.52 0.39–0.71
14 Translational elongation 4.15 × 10−9 7.47 × 10−8 0.48 0.37–0.63
4 None 4.78 × 10−7 8.61 × 10−6 0.45 0.32–0.63
Gene set
FMRP Synaptic transmission <2.2 × 10−16 1.87 1.62–2.14
LoF Regulation of transcription <2.2 × 10−16 1.42 1.31–1.53
Note: Gene sets were collated from Parikshak et al (weighted gene co-expression network, human neocortical development), Darnell 
et al (FMRP bound genes) and Lek et al (LoF intolerant genes).37,38,46 Initial P values were generated using Fisher’s exact test and were 
corrected (P corr) for multiple testing (Bonferroni) where appropriate. Only P values <.05 were considered statistically significant. OR, 
odds ratio; CI, confidence interval; NS, not significant.
aPrinicipal ontology for each module or gene set.
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are representative of neuronal gene expression pathways 
that regulate important neurodevelopmental cellular pro-
cesses in human brain.
TCF4 Targets and Neuropsychiatric Disease Risk Genes
Given the association of TCF4 variants with schizo-
phrenia and other neurodevelopmental disorders, we 
examined the enrichment of TCF4 targets with genes as-
sociated with different diseases. Firstly, we determined the 
overlap of TCF4 targets with loci associated with schiz-
ophrenia through common genetic variation.4 Forty-nine 
schizophrenia risk loci (45.4%) contained TCF4 binding 
sites out of 108 GWAS significant schizophrenia risk loci. 
A total of 4168 genes were present in both the TCF4 target 
and schizophrenia risk loci datasets. We used MAGMA 
to test for association between TCF4 bindings sites and 
schizophrenia (PGC2 GWAS) correcting for gene length 
and linkage disequilibrium (LD).39 MAGMA reported a 
nominally significant enrichment of TCF4 target genes 
amongst schizophrenia risk loci (P = .049) after correct-
ing for gene length and LD.
Although there was only nominal enrichment of TCF4 
targets in the GWAS significant schizophrenia risk loci, 
several schizophrenia risk genes were found to contain 
TCF4 binding sites. As described above, the CHRNA5/
A3/B4 locus contained several TCF4-binding sites in reg-
ulatory regions including a distal enhancer (figure 2C). 
Other schizophrenia risk loci with TCF4 binding sites in-
clude DRD2, TSNARE1, and GRIA1, all of which are 
down-regulated in TCF4-depleted cells and MIR137/
DPYD. Furthermore, several TCF4 binding sites are 
also located within the TCF4 gene itself  suggesting that 
TCF4 may autoregulate the expression of its numerous 
distinct isoforms.24 In addition to the common variant 
schizophrenia risk loci, rare LoF mutations in SETD1A 
have recently been associated with schizophrenia and 
developmental disorders.49,50 SETD1A, that encodes 
a histone methyltransferase, has a TCF4 binding site 
(chr16:30968306–30969367) at its TSS, potentially impli-
cating both schizophrenia risk genes in the same regula-
tory network.
Next, we determined the overlap between TCF4 bound 
genes and de novo variants found in individuals with 
schizophrenia collated by Fromer et al.36 For schizo-
phrenia de novos, statistically significant enrichment was 
observed for all classes of mutations bar silent mutations 
(table 2); all mutations (SCZ_all P = 5.25 × 10−7), loss 
of function mutations (SCZ_LoF P = 2.79 × 10−2) and 
nonsynonymous mutations (SCZ_NS, P = 1.26 × 10−5). 
Importantly, no enrichment was observed in the con-
trol datasets derived from unaffected siblings and con-
trols irrespective of mutation type. Finally, we examined 
the overlap between TCF4 bound genes and loci impli-
cated in ID and ASD through de novo mutations (table 
2). Significant enrichment also was detected in both ID 
and ASD for all mutations types (ID_all P = 7.61 × 10−3; 
ASD_all P = 2.46 × 10−4) and for nonsynonymous muta-
tions (ID_NS P = 2.04 × 10−3; ASD_NS P = 1.57 × 10−4). 
Silent mutations and the most damaging LoF mutations 
were not enriched in either ID or ASD de novos.
Discussion
The transcription factor TCF4 has been implicated in 
the genetic aetiology of several neuropsychiatric and 
Table 2. Gene Set Enrichment for TCF4 Bound Genes and Neuropsychiatric Disease Risk Genes
Gene Set Gene Count P Value P Corr. OR 95% CI
SCZ_all 862 3.28 × 10−8 5.25 × 10−7 1.55 1.33–1.81
SCZ_LoF 98 1.74 × 10−3 2.79 × 10−2 1.99 1.31–3.03
SCZ_NS 668 7.90 × 10−7 1.26 × 10−5 1.56 1.31–1.85
SCZ_silent 207 1.02 × 10−2 NS 1.5 1.11–2.03
ASD_all 951 1.54 × 10−5 2.46 × 10−4 1.39 1.20–1.62
ASD_LoF 124 3.54 × 10−2 NS 1.53 1.04–2.27
ASD_NS 724 9.84 × 10−6 1.57 × 10−4 1.47 1.25–1.74
ASD_silent 248 2.40 × 10−1 NS 1.20 0.89–1.60
ID_all 154 4.76 × 10−4 7.61 × 10−3 1.86 1.33–2.61
ID_LoF 30 2.60 × 10−1 NS 1.6 0.73–3.51
ID_NS 129 1.28 × 10−4 2.04 × 10−3 2.09 1.45–2.99
ID_silent 25 1.00 NS 0.94 0.35–2.49
Control/sibling_all 557 8.39 × 10−3 NS 1.3 1.07–1.58
Control/sibling_LoF 49 3.80 × 10−1 NS 1.35 0.72–2.55
Control/sibling_NS 417 5.98 × 10−2 NS 1.25 1.00–1.56
Control/sibling_silent 151 7.15 × 10−2 NS 1.4 0.98–2.00
Note: Statistical enrichment for TCF4 bound genes in gene sets derived from exome sequencing studies in schizophrenia, ID and ASD 
using gene sets were collated from Fromer et al.36 Initial P values were generated using Fisher’s exact test and were corrected (P corr.) for 
multiple testing (Bonferroni). Only P values <.05 were considered statistically significant. OR, odds ratio; CI, confidence interval; NS, 
not significant.
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neurological disorders, however, the identity of TCF4 
target genes in neuronal cells remains largely unknown. 
In this study, we define the genome-wide TCF4 binding 
sites in the commonly used SH-SY5Y neuroblastoma 
cell line. As predicted from earlier in vitro studies, we 
found that the majority of TCF4 binding sites (85.8%) 
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in the genome contained at least one canonical E-box 
within 200 bp of the peak maximum.23 Furthermore, de 
novo motif  discovery showed that TCF4 binding sites 
were enriched for the nonpalindromic E-box sequence, 
5′-CAtcTG (figure 1C). Interestingly, 77% of the TCF4 
binding sites overlapped active enhancers marked by 
H3K27ac and H3K4me1 in SH-SY5Y cells (figure 2). 
Conversely, only 1.7% of TCF4 peaks were marked by 
H3K4me3 in agreement with the low percentage of TCF4 
binding sites at the promoter-TSS region of genes (figure 
1B). Taken together, these data demonstrate that TCF4 is 
an E-box-binding transcription factor that preferentially 
associates with active enhancers in SH-SY5Y cells.
To understand how TCF4 binding modulates gene 
expression, we intersected the list of  ChIP-defined tar-
gets with the list of  differentially expressed genes fol-
lowing acute TCF4 knockdown in SH-SY5Y cells.41 
Differentially expressed genes were significantly under-
represented among the set of  TCF4 targets (figure 1D). 
Although this finding seems counterintuitive, large 
scale studies transcriptomic studies have found that 
functional transcription factor binding occurs at only 
a small subset of  genes.42 Furthermore, several differ-
entially expressed TCF4 targets such as NEUROG2, 
SNAI2, and DACH1 are transcriptional regulators 
whose altered expression will also contribute to tran-
scriptional dysregulation in TCF4-depeleted cells. 
Given the large number of  TCF4 bound genes identi-
fied, we used enrichment analysis to group biological 
processes involving TCF4 targets en masse. Consistent 
with a neurodevelopmental role for TCF4, TCF4’s ge-
nomic targets cluster into ontologies associated with 
a wide variety of  cellular functions including nervous 
system development and signal transduction (figures 
2B and 3; supplementary figure 3).
One of  the principal aims of  this study was to deter-
mine whether TCF4 binds and regulates genes implicated 
in the aetiology of  complex neuropsychiatric disorders. 
Given the association of  TCF4 common variants with 
schizophrenia, we initially focused on TCF4 binding 
sites in schizophrenia risk loci identified in the most 
comprehensive genome wide association study published 
to date.4 Although there was only nominal enrichment 
of  TCF4 targets among the genome-wide significant 
schizophrenia loci, many schizophrenia susceptibility 
loci contain functional TCF4 binding sites such as the 
CHRNA5/A3/B4 locus which encodes subunits of  the 
nAChR. In addition to schizophrenia, the CHRNA5/A3/
B4 locus is a risk factor for nicotine dependence, smoking 
behavior, and lung cancer.51,52 CHRNA3 polymorphisms 
are associated with sensorimotor gating, measured be 
prepulse inhibition (PPI), in schizophrenia patients and 
controls.53 Interestingly, nicotine administration essen-
tially normalized the effects CHRNA3 genotype on PPI 
suggesting that nicotine may interact with CHRNA3 
variants to modulate sensorimotor gating.54 Similarly, 
schizophrenia-associated TCF4 risk variants also influ-
ence sensorimotor gating and interact with smoking be-
havior to modulate this neurophysiological response.8,9 
Our finding that TCF4 directly regulates transcription of 
the CHRNA5/A3/B4 cluster may provide a mechanistic 
explanation for the interaction between TCF4 common 
variants with smoking behavior on auditory sensori-
motor gating; considered to be an endophenotype of 
schizophrenia. Clearly, further research will be required 
to unravel the functional effects of  cis-acting variants at 
the CHRNA5/A3/B4 locus with TCF4 and other tran-
scriptional regulators in schizophrenia and other neuro-
developmental disorders.
In addition to schizophrenia, we found a significant 
enrichment for TCF4 targets associated with genes impli-
cated in ASD and to a lesser extent ID (table 2). We also 
observed similar convergence between TCF4 targets and 
ASD risk genes represented in co-expression modules 
during cortical development in humans (table 1). Notably, 
module 17 that contain genes involved in synaptic trans-
mission are enriched for both inherited, common variant 
ASD-risk genes and TCF4 targets.46 Furthermore, a ro-
bust overlap exists between targets of the FMRP RNA-
binding protein and genes implicated in a range of brain 
disorders including schizophrenia and ASD.36,55 We found 
that many TCF4 bound genes are also FMRP targets, in-
cluding TCF4 itself  (table 1). The overlap between FMRP 
targets and TCF4-bound regions of the genome suggests 
that both genes may operate in a similar pathway. It is 
clear that TCF4 and FMRP, the protein product of the 
fragile X syndrome ID gene, have regulatory functions 
in neurons that are essential for normal cognitive devel-
opment and synaptic plasticity.25,56 Furthermore, FMRP 
and TCF4 are regulated by neuronal activity suggest-
ing that their activities may be co-regulated.57,58 Finally, 
protein truncating mutations in a subset of LoF intol-
erant genes are frequently found in individuals with ASD 
ND ID/developmental delay (DD).59 The enrichment of 
TCF4 targets among LoF intolerant genes lends further 
support to a convergent role for TCF4 regulated gene ex-
pression networks in mediating elements of the disease 
risk mechanism in a range of neurodevelopmental disor-
ders (table 1).
In conclusion, the identification of genome-wide bind-
ing sites for TCF4 provides an insight into the biological 
processes regulated by TCF4 in human cells. The iden-
tification of a large repertoire of TCF4 regulated genes 
in cells of neuronal origin will provide a useful adjunct 
for the interpretation of regulatory processes in the brain. 
Applying this information to common psychiatric disor-
ders may provide a mechanistic insight into the shared 
genetic aetiology between different diagnoses, yielding 
functional regulatory interactions among candidate risk 
genes.
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